EUCTR2014-003265-19-PL进行中（未招募）1 期
A Long-Term Follow-up Study Assessing the Safety and Efficacy of Vatelizumab in Multiple Sclerosis (MS) Patients Who Completed Treatment in Study DRI13839
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 168
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •Patients who completed the 12-week treatment period in DRI13839.
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 168
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •Any clinically significant or ongoing adverse events, or laboratory abnormalities from DRI13839 that per Investigator judgment would adversely affect the patient’s participation in the long-term extension study.
- •Confirmed platelet count below the lower limit of normal at any time during DRI13839.
- •Pregnancy or breast-feeding.
研究者
相似试验
进行中（未招募）
1 期
A clinical study to learn about the effects of a virus that transfers the gene for human coagulation factor IX in adults with moderate/severe to severe inherited coagulations defects in the long termModerate/severe to severe hemophilia BMedDRA version: 20.0 Level: LLT Classification code 10060614 Term: Hemophilia B (Factor IX) System Organ Class: 100000004850EUCTR2016-003430-25-GBltragenyx Pharmaceutical, Inc.6
进行中（未招募）
1 期
A clinical study to learn about the effects of a virus that transfers the gene for Glucose- 6-Phosphatase (G6Pase) in adults with Glycogen Storage Disease Type IaEUCTR2018-004473-27-ESltragenyx Pharmaceutical Inc.12
进行中（未招募）
1 期
A clinical study to learn about the effects of a virus that transfers the gene for Glucose- 6-Phosphatase (G6Pase) in adults with Glycogen Storage Disease Type IaCTIS2023-504004-29-00ltragenyx Pharmaceutical Inc.12
进行中（未招募）
1 期
A clinical study to learn about the effects of a virus that transfers the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiency in the long termOrnithine transcarbamylase deficiencyEUCTR2018-000156-18-FRltragenyx Pharmaceutical, Inc.18
进行中（未招募）
1 期
A clinical study to learn about the effects of a virus that transfers the gene for human Ornithine Transcarbamylase (OTC) in adults with late-onset OTC deficiency in the long termOrnithine transcarbamylase deficiencyMedDRA version: 20.0Level: LLTClassification code: 10071107Term: Ornithine transcarbamylase deficiency Class: 10010331CTIS2022-501146-30-00ltragenyx Pharmaceutical Inc.11